1 / 7

Factors That Increase the Risk of Myopathy in People Taking Statins

Factors That Increase the Risk of Myopathy in People Taking Statins. 5) Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005; 95: 120–122.

nansen
Download Presentation

Factors That Increase the Risk of Myopathy in People Taking Statins

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Factors That Increase the Risk of Myopathy in People Taking Statins 5) Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005; 95: 120–122. 6) Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; 289: 1681–1690. 7) Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001; 35: 26–31. 8) Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003; 163: 553–564. 9) Foody JM, Krumholz HM. Are statins indicated for the primary prevention of CAD in octogenarians? Antagonist viewpoint. Am J Geriatr Cardiol. 2003; 12: 357–360. 24) Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000; 102: 1893–1900. 35) Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004; 109 (suppl I): III-50–III-57. Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

  2. Relation between reduction in incidence of CV events and mean LDL cholesterol reduction in major statin trials Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

  3. Event rates plotted vs LDL cholesterol levels during statin therapy in secondary-prevention studies Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

  4. Coronary heart disease event rate in men and women as a function of HDL cholesterol levels in the Framingham Heart Study Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

  5. Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (pravastatin 40 mg in WOSCOPS) Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

  6. Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (pravastatin 40 mg in the LIPID and CARE trials) Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

  7. Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (simvastatin 40 mg in the HPS) Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315-1320

More Related